Executive Director, Early Clinical Development

Role: Executive Director of Early Clinical Development, leading the strategic planning and operational execution of clinical programs for Revolution Medicines' RAS(ON) inhibitors in oncology. Responsibilities: oversee clinical trial design, site management, data interpretation, regulatory interactions, and cross-functional team leadership; develop and implement development strategies aligned with scientific and regulatory goals; manage stakeholder relationships and ensure milestone achievement from early trials to potential regulatory submissions. Requirements: MD, PhD, or equivalent with 13+ years in pharma/biotech or academia; extensive experience in clinical trial design, early-phase drug development (Phase 1), regulatory interactions, and multi-disciplinary leadership; strong knowledge of GCP, ICH, FDA, EMA guidelines; proven track record of successful clinical development and regulatory submissions; excellent strategic, communication, and leadership skills. Preferred: experience with NDA/BLA submissions, regulatory authority interactions, phase IV studies, and process improvements; demonstrated ability to serve as a company spokesperson and lead enterprise-level initiatives. HighValue: oncology, RAS pathway, novel targeted therapies, clinical-stage molecules, early to late-phase development, regulatory engagement, cross-functional collaboration, onsite Redwood City, CA; no explicit travel expectations stated.